DYANAVEL XR DIN 02559781
Status: Approved
Holder: KYE PHARMACEUTICALS INC.
Health Canada record
| Active ingredient(s) | AMPHETAMINE (AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE (COMPLEXED WITH SODIUM POLYSTYRENE SULFONATE)) 2.5 MG |
|---|---|
| Dosage form | Suspension (Extended-Release) |
| Route | Oral |
| Schedule | CONTROLLED DRUGS (CDSA I) |
| Class | Human |
| ATC | N06BA01 AMFETAMINE |
| Original market date | |
| Current status date | 28-Jul-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
KYE Pharmaceuticals Inc. — licence 3-002615, currently licensed, last inspection rating C (2025-09-08).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AMPHETAMINE (AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE (COMPLEXED WITH SODIUM POLYSTYRENE SULFONATE))
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02559803 | DYANAVEL XR | KYE PHARMACEUTICALS INC. | Tablet (Extended-Release) | AMPHETAMINE (AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE (COMPLEXED WITH SODIUM POLYSTYRENE SULFONATE)) 5 MG | Marketed |
| 02559811 | DYANAVEL XR | KYE PHARMACEUTICALS INC. | Tablet (Extended-Release) | AMPHETAMINE (AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE (COMPLEXED WITH SODIUM POLYSTYRENE SULFONATE)) 10 MG | Marketed |
| 02559838 | DYANAVEL XR | KYE PHARMACEUTICALS INC. | Tablet (Extended-Release) | AMPHETAMINE (AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE (COMPLEXED WITH SODIUM POLYSTYRENE SULFONATE)) 15 MG | Marketed |
| 02559846 | DYANAVEL XR | KYE PHARMACEUTICALS INC. | Tablet (Extended-Release) | AMPHETAMINE (AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE (COMPLEXED WITH SODIUM POLYSTYRENE SULFONATE)) 20 MG | Marketed |